1-3 of 3
Rodolfo E. Bordoni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Clinical Trials & Observations
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J. M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood
Blood (2017) 130 (26): 2829–2837.
https://doi.org/10.1182/blood-2017-06-787200
Published: 2017
Includes: Supplemental data
Journal Articles

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Clinical Trials & Observations
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, Robert Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo E. Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood
Blood (2015) 126 (26): 2798–2804.
https://doi.org/10.1182/blood-2015-06-644336
Published: 2015
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Christopher A. Yasenchak, MD, Andres Forero-Torres, Vivian Jean Mikao Cline-Burkhardt, Rodolfo E Bordoni, MD, Dipti Patel-Donnelly, MD, Patrick J. Flynn, MD, Robert Chen, Abraham Fong, Jonathan W. Friedberg, MD MMSc
Journal: Blood
Blood (2015) 126 (23): 587.
https://doi.org/10.1182/blood.V126.23.587.587
Published: 2015